发明名称 |
C-MET-TARGETING FULL AGONIST HUMAN ANTIBODY WITH HGF ACTIVITY AND USAGE THEREOF |
摘要 |
PURPOSE: A human antibody which is derived from human body and specifically binds to c-Met is provided to treat neuronal infarction, progressive nephropathy, liver cirrhosis, lung fibrosis, kidney, liver, lung injury, and ulcerative wound which are cured by HGF or c-Met activation. CONSTITUTION: A human antibody contains a complementarity determining region (CDR) and framework region(FR) which are derived from human and specifically binds to c-Met. The human antibody contains: a heavy chain variable region containing heavy chain CDR1 of sequence number 1, heavy chain CDR2 of sequence number 2, and heavy chain CDR3 of sequence number 3; and a light chain variable region containing light chain CDR1 of sequence number 4, light chain CDR2 of sequence number 5, and light chain CDR3 of sequence number 6. The antibody contains a heavy chain variable region amino acid of sequence number 7 and a light chain variable region amino acid of sequence number 8. The human antibody is glycosylated or/and PEGylated. A composition for wound healing contains the human antibody as an active ingredient and pharmaceutically acceptable carrier. A composition for treating neurodegenerative diseases contains the human antibody as an active ingredient and pharmaceutically acceptable carrier. |
申请公布号 |
KR20120134938(A) |
申请公布日期 |
2012.12.12 |
申请号 |
KR20110054177 |
申请日期 |
2011.06.03 |
申请人 |
KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY;A&R THERAPEUTICS CO., LTD. |
发明人 |
PARK, YOUNG WOO;JO, KI WON;PARK, CHAN WOONG;YOO, SEOK HO;JANG, MYEOUNG HEE;KIM, HYE NAN;YUN, SEON HA;CHO, KYU WON;PARK, MI RA |
分类号 |
C07K16/22;A61K39/395;A61P25/28;C12N15/13 |
主分类号 |
C07K16/22 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|